eXoZymes (EXOZ) Competitors $12.40 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EXOZ vs. DSGN, CGC, LRMR, ALT, AMRN, GLUE, OCGN, TECX, DRUG, and FDMTShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Design Therapeutics (DSGN), Canopy Growth (CGC), Larimar Therapeutics (LRMR), Altimmune (ALT), Amarin (AMRN), Monte Rosa Therapeutics (GLUE), Ocugen (OCGN), Tectonic Therapeutic (TECX), Bright Minds Biosciences (DRUG), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Design Therapeutics Canopy Growth Larimar Therapeutics Altimmune Amarin Monte Rosa Therapeutics Ocugen Tectonic Therapeutic Bright Minds Biosciences 4D Molecular Therapeutics eXoZymes (NASDAQ:EXOZ) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment. Is EXOZ or DSGN more profitable? Design Therapeutics' return on equity of -27.15% beat eXoZymes' return on equity.Company Net Margins Return on Equity Return on Assets eXoZymesN/A -134.50% -81.63% Design Therapeutics N/A -27.15%-26.07% Do institutionals & insiders hold more shares of EXOZ or DSGN? 56.6% of Design Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 23.5% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, EXOZ or DSGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymesN/AN/A-$5.86MN/AN/ADesign TherapeuticsN/AN/A-$49.59M-$1.12-5.38 Does the media favor EXOZ or DSGN? In the previous week, Design Therapeutics had 1 more articles in the media than eXoZymes. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.91 beat Design Therapeutics' score of 1.21 indicating that eXoZymes is being referred to more favorably in the media. Company Overall Sentiment eXoZymes Very Positive Design Therapeutics Positive SummaryDesign Therapeutics beats eXoZymes on 4 of the 7 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.00M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.4375.3425.98Price / SalesN/A429.47514.55181.19Price / CashN/A46.6837.5660.44Price / Book9.929.6112.156.29Net Income-$5.86M-$53.29M$3.29B$271.07M7 Day Performance3.68%0.13%0.74%3.87%1 Month Performance24.12%5.61%4.82%4.88%1 Year PerformanceN/A10.49%60.58%26.12% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymes1.2307 of 5 stars$12.40flatN/AN/A$104.00MN/A0.0029Positive NewsDSGNDesign Therapeutics0.2633 of 5 stars$6.11+2.5%N/A+3.3%$339.41MN/A-5.4640Positive NewsCGCCanopy Growth0.9398 of 5 stars$1.38-1.4%N/A-71.0%$335.79M$225.65M-0.463,150Positive NewsShort Interest ↓Gap UpLRMRLarimar Therapeutics2.616 of 5 stars$3.87-1.8%$18.43+376.2%-45.7%$326.14MN/A-2.4830ALTAltimmune2.7128 of 5 stars$3.56-3.3%$17.40+388.8%-48.7%$324.79M$20K-3.0250AMRNAmarin0.6115 of 5 stars$15.03-0.1%$12.00-20.2%+29.0%$311.07M$228.61M-4.10360GLUEMonte Rosa Therapeutics2.7086 of 5 stars$4.91-1.8%$15.33+212.3%-19.3%$308.80M$75.62M13.6490Positive NewsOCGNOcugen1.7649 of 5 stars$1.03-1.9%$6.00+482.5%-10.8%$306.92M$4.05M-5.1580TECXTectonic Therapeutic3.0947 of 5 stars$17.27+5.8%$80.29+364.9%+1.3%$305.48MN/A-4.27120Positive NewsHigh Trading VolumeDRUGBright Minds Biosciences3.3006 of 5 stars$43.95+1.6%$83.25+89.4%+3,800.0%$304.79MN/A-47.26N/APositive NewsGap UpHigh Trading VolumeFDMT4D Molecular Therapeutics2.6766 of 5 stars$6.61+2.2%$30.40+359.9%-57.2%$302.17M$40K-1.87120News CoveragePositive News Related Companies and Tools Related Companies Design Therapeutics Competitors Canopy Growth Competitors Larimar Therapeutics Competitors Altimmune Competitors Amarin Competitors Monte Rosa Therapeutics Competitors Ocugen Competitors Tectonic Therapeutic Competitors Bright Minds Biosciences Competitors 4D Molecular Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
